Skip to main content

Table 1 Patient characteristics

From: Filtration based assessment of CTCs and CellSearch® based assessment are both powerful predictors of prognosis for metastatic breast cancer patients

Group    
Age, years (mean, SD)   60.9 11.2
Body mass index (mean, SD)   26.9 6.1
Tumor stage (n, %) T1 18 30.0
  T2–4 40 66.6
  n.a. 2 3.3
N-staging (n, %) N+ 36 60.0
  N0 18 30.0
  n.a. 6 10.0
ER (n, %) Positive 42 70.0
  Negative 17 28.3
  n.a. 1 1.7
PR (n, %) Positive 38 63.3
  Negative 21 35.0
  n.a. 1 1.7
HER2 (n, %) Positive 12 20.0
  Negative 41 68.3
  n.a. 7 11.7
Grading (n, %) G1 4 6.7
  G2 27 45.0
  G3 28 46.7
  n.a. 1 1.7
Histopathological subtype (n, %) Ductal 50 83.3
  Lobular 7 11.7
  Others 2 3.4
  n.a. 1 1.7
Treatment linea (n, %) First line 16 26.7
  Second line 12 20.0
  Third line 12 20.0
  Higher 18 30.0
  n.a. 2 3.3
Treatment at blood draw (n, %) Chemotherapy 27 45.0
AH 18 30.0
  Othersb 42 70.0
  1. aTherapy lines are either chemotherapies, antihormone therapies or other anti-cancer treatments. Each initiated therapy line is counted as one regardless of whether a disease progression triggered the therapy initiation
  2. be.g. bone modifying drugs or monoclonal antibodies
\